Patents Represented by Attorney Clark & Elbing LLP
  • Patent number: 7785594
    Abstract: The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VII to levels between 40 and 95%. The present invention further disclosed pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures.
    Type: Grant
    Filed: August 16, 2004
    Date of Patent: August 31, 2010
    Assignee: Life Sciences Research Partners VZW
    Inventors: Jean-Marie Saint-Remy, Marc Jacquemin
  • Patent number: 7780951
    Abstract: The invention relates to the immunization of pigs against Candidatus Helicobacter suis using antigens of species related to Candidatus Helicobacter suis.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: August 24, 2010
    Assignee: Universiteit Gent
    Inventors: Richard Ducatelle, Ann Hellemans
  • Patent number: 7771727
    Abstract: The invention features conjugates of therapeutic or cytotoxic agents and biologically active peptides and methods of use thereof.
    Type: Grant
    Filed: March 3, 2003
    Date of Patent: August 10, 2010
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: Joseph A. Fuselier, David H. Coy
  • Patent number: 7772251
    Abstract: The present invention relates to N-sulfonylated amino acid derivatives, where an aryl radical is linked via the sulfonyl group N-terminally to the amino acid and a radical which comprises at least one imino group and at least one further basic group which represents an optionally modified amino, amidino or guanidino group is linked C-terminally via the carbonyl group. The invention likewise relates to processes for preparing these compounds and to their use, in particular as inhibitors of matriptase.
    Type: Grant
    Filed: May 17, 2004
    Date of Patent: August 10, 2010
    Assignee: The Medicines Company (Leipzig) GmbH
    Inventors: Jörg Stürzebecher, Torsten Steinmetzer, Andrea Schweinitz, Anne Stürzebecher, Kerstin Uhland
  • Patent number: 7771931
    Abstract: The invention provides methods of diagnosing diseases and conditions associated with PKC?, methods for identifying compounds that can be used to treat or to prevent such diseases and conditions, and methods of using these compounds to treat or to prevent such diseases and conditions. Also provided in the invention are animal model systems that can be used in screening methods.
    Type: Grant
    Filed: September 6, 2002
    Date of Patent: August 10, 2010
    Assignee: The General Hospital Corporation
    Inventors: Randall Peterson, Mark C. Fishman
  • Patent number: 7767787
    Abstract: The invention relates to a substance and a process for obtaining anti-tumor agents.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: August 3, 2010
    Assignee: Debiovision Inc.
    Inventors: Heinz Peter Vollmers, Hans Konrad Mueller-Hermelink
  • Patent number: 7763712
    Abstract: A bone delivery conjugate having a structure selected from the group consisting of: A) X-Dn-Y-protein-Z; and B) Z-protein-Y-Dn-X, wherein X is absent or is an amino acid sequence of at least one amino acid; Y is absent or is an amino acid sequence of at least one amino acid; Z is absent or is an amino acid sequence of at least one amino acid; and Dn is a poly aspartate wherein n=10 to 16. Compositions comprising same and methods of use thereof.
    Type: Grant
    Filed: April 21, 2005
    Date of Patent: July 27, 2010
    Assignee: Enobia Pharma Inc.
    Inventors: Philippe Crine, Guy Boileau, Isabelle Lemire, Thomas P. Loisel
  • Patent number: 7758859
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Grant
    Filed: April 27, 2006
    Date of Patent: July 20, 2010
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic A. Fellouse, Sachdev S. Sidhu, Christian Wiesmann
  • Patent number: 7754479
    Abstract: The present invention relates to a method for long-term culturing of avian spermatogonial stem cells, which comprises the steps of: (a) preparing an avian testis; (b) isolating a population of testicular cells from said avian testis; and (c) culturing said avian spermatogonial stem cells in said population of testicular cells on a feeder cell layer in a medium containing a cell growth factor, a population of avian spermatogonial stem cells and a method for producing transgenic ayes.
    Type: Grant
    Filed: August 6, 2004
    Date of Patent: July 13, 2010
    Assignees: Seoul National University Industry Foundation, Avicore Biotechnology Institute Inc.
    Inventors: Jae Yong Han, Yeong Ho Hong, Jeong Mook Lim, Young Mok Lee, Mak Soon Lee, Jin Gyung Jung
  • Patent number: 7754215
    Abstract: The present invention clearly demonstrates that vWF-collagen interaction, via the A3 domain of vWF, plays an important role in acute platelet-dependent arterial thrombus formation and that blocking the A3 domain in a vWF-collagen interaction can induce complete abolition of thrombus formation in the injured and stenosed baboon femoral arteries. Accordingly, an antibody or an antigen recognizing fragment thereof binding specifically to the A3 domain of vWF or an epitope thereof can be used for the prevention of acute arterial thrombotic syndromes or to manufacture medicines to for the prevention of acute arterial thrombotic syndromes.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: July 13, 2010
    Assignee: K.U. Leuven Research & Development
    Inventors: Hans Deckmyn, Nancy Cauwenberghs, Karen Vanhoorelbeke
  • Patent number: 7749521
    Abstract: The invention describes a new class of crystalline silica material having two levels or porosity and structural order. At the first level, building units are nanoslabs of uniform size having zeolite framework. At the second structural level, nanoslabs are assembled, e.g. linked through their corners, edges or faces following patterns imposed by interaction with cationic surfactant or triblock copolymer molecules. After evacuation of these molecules, microporosity is obtained inside the nanoslabs, and a precise mesoporosity between the nanoslabs depending on the tiling pattern of the zeolite nanoslabs, as evidenced by X-ray diffraction. These materials are useful for the fixation of biologically active species, such as poorly soluble drugs.
    Type: Grant
    Filed: June 28, 2004
    Date of Patent: July 6, 2010
    Assignee: K.U. Leuven Research & Development
    Inventors: Johan Adriaan Martens, Christine Eva Antonia Kirschhock, Sebastien Philippe Brigitte Kremer, Alexander Jan Maria Herman Eugeen Aerts, Guy Van Den Mooter, Jan Van Humbeeck
  • Patent number: 7749745
    Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: July 6, 2010
    Assignees: Georgetown University, The General Hospital Corporation, MediGene, Inc.
    Inventors: Paul Johnson, Robert L. Martuza, Samuel D. Rabkin, Tomoki Todo
  • Patent number: 7750536
    Abstract: In one aspect, matching layers for an ultrasonic transducer stack having a matching layer comprising a matrix material loaded with a plurality of micron-sized and nano-sized particles. In another aspect, the matrix material is loaded with a plurality of heavy and light particles. In another aspect, an ultrasound transducer stack comprises a piezoelectric layer and at least one matching layer. In one aspect, the matching layer comprises a composite material comprising a matrix material loaded with a plurality of micron-sized and nano-sized particles. In a further aspect, the composite material can also comprise a matrix material loaded with a plurality of heavy and light particles. In a further aspect, a matching layer can also comprise cyanoacrylate.
    Type: Grant
    Filed: March 2, 2006
    Date of Patent: July 6, 2010
    Assignee: Visualsonics Inc.
    Inventors: N. Chris Chaggares, James Mehi, Desmond Hirson
  • Patent number: 7749969
    Abstract: N- or C-terminally modified small peptides having antiarrhythmic properties are disclosed, and in particular small peptides that possess improved pharmacokinetic properties such as having a reduced tendency to inhibit the activity of isozyme 3A4 of cytochrome P 450 oxidase. The invention further relates to uses of said compounds in the preparation of a medicament, and to pharmaceutical compositions comprising said compounds.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: July 6, 2010
    Assignees: Zealand Pharma A/S, Wyeth
    Inventors: Bjarne Due Larsen, Edward H. Kerns
  • Patent number: 7745403
    Abstract: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g., as assessed in in vitro stability assays. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 8, 16, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 (as mentioned in the introduction) and one or more of positions 3, 5, 7, 10 and 11, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy. Also disclosed are methods and kits for selecting a patient from populations suited for treatment with GLP-2 analogues.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: June 29, 2010
    Assignee: Zealand Pharma A/S
    Inventors: Bjarne Due Larsen, Yvette Miata Petersen
  • Patent number: 7745575
    Abstract: OsK1 is a 38-residue peptide with 3 disulphide bridges and is found in the venom of the scorpion Orthochirus scrobiculosus. It is potently active on voltage-gated K+ channels Kv1.1, Kv1.2 and Kv1.3, and moderately active on the type 1 intermediate-conductance Cat2+-activated channel KCa3.1. Derivatives of OsK1, particularly involving truncation or point mutations, have been developed to enhance the activity against and selectivity for the Kv1.3 channel. This renders the derivatives likely candidates for the treatment of autoimmune diseases, including multiple sclerosis. Such use may be alone or in combination therapy with maurotoxin, another scorpion toxin.
    Type: Grant
    Filed: June 27, 2005
    Date of Patent: June 29, 2010
    Assignee: Cellpep Pharma Inc.
    Inventors: Stephanie Mouhat, Jean-Marc Sabatier, Bonabes Olivier de Rouge
  • Patent number: 7744912
    Abstract: The invention features polymeric biomaterials formed by nucleophilic addition reactions to conjugated unsaturated groups. These biomaterials may be used for medical treatments.
    Type: Grant
    Filed: February 1, 2000
    Date of Patent: June 29, 2010
    Assignees: Eidgenossische Technische Hochschule Zurich, Universitat Zurich
    Inventors: Jeffrey A. Hubbell, Donald Elbert, Matthias Lütolf, Alison Pratt, Ronald Schoenmakers, Nicola Tirelli, Brent Vernon
  • Patent number: 7745396
    Abstract: Compositions and methods for antiplatelet/anti-thrombotic therapy in a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1 admixed with a pharmaceutically acceptable carrier to a subject in need of such therapy. Methods of administering SERP-1 with at least one other antiplatelet agent are also provided. The compositions and methods of the present invention are useful for treating and preventing recurrence of numerous cardiovascular diseases and injuries.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: June 29, 2010
    Assignee: Viron Therapeutics Inc.
    Inventor: Alexandra Lucas
  • Patent number: 7745443
    Abstract: The present invention relates to compounds of the formula I, in which R1, R2, A, B, D, E, n, m or o have the meanings indicated below. The compounds of the formula I are valuable pharmacologically active compounds. They are reversible inhibitors of the interaction between the plasma protein von Willebrand factor (vWF) and the blood platelet receptor glycoprotein Ib-IX-V complex (GPIb). They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of atherothrombotic diseases.
    Type: Grant
    Filed: April 2, 2007
    Date of Patent: June 29, 2010
    Assignees: Sanofi-Aventis Deutschland GmbH, Ajinomoto Co., Inc.
    Inventors: Otmar Klingler, Melitta Just, Kuniya Sakurai, Naoyuki Fukuchi
  • Patent number: 7741529
    Abstract: The present invention refers to non-human transgenic mammals, preferably rodents, or mice, which comprise a mutation in the gene encoding for the cardiac ryanodine receptor (RyR2). Transgenic animals carrying the amino acid change R4496C in the RyR2 protein show a phenotype similar to that of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (OMIM: 604772). Further provided are methods for using these animals as in vivo model of Catecholaminergic Polymorphic Ventricular Tachycardia and RyR2 dependent arrhythmias, in drug screening and for understanding the molecular basis of RyR2 dependent arrhythmias.
    Type: Grant
    Filed: May 4, 2006
    Date of Patent: June 22, 2010
    Inventors: Silvia G. Priori, Carlo Napolitano